Viewing Study NCT05866692


Ignite Creation Date: 2025-12-24 @ 3:21 PM
Ignite Modification Date: 2025-12-27 @ 5:46 PM
Study NCT ID: NCT05866692
Status: RECRUITING
Last Update Posted: 2023-11-07
First Post: 2023-05-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor: TYK Medicines, Inc
Organization:

Study Overview

Official Title: A Phase I, Multicenter, Open-label Study of TY-2699a, Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Status: RECRUITING
Status Verified Date: 2023-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
Detailed Description: To assess the safety and tolerability of TY-2699a when administered as a single agent in subjects with locally advanced or metastatic solid tumors.

To determine the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) as a single agent in subjects with locally advanced or metastatic solid tumors.

To evaluate the pharmacokinetics (PK) of TY-2699a administered at single and multiple oral doses.

To assess the preliminary antitumor activity of TY-2699a as a single agent in subjects with locally advanced or metastatic solid tumors.

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: